Local Approach to Asthma

PRS-060 is Pieris’ lead respiratory Anticalin®-based drug candidate, developed in collaboration with AstraZeneca. PRS-060 blocks the IL-4Rα immunoreceptor, inhibiting small IL-4 and IL-3 proteins that drive a cascade of inflammatory responses in the lungs.

The small size and stability of PRS-060 allow the drug to be inhaled directly into the lungs, rather than injected, potentially achieving the same benefits as systemic treatments, but with lower doses and fewer side effects. Phase 1 trials have shown significantly reduced levels of fractional exhaled nitric oxide (FeNO), a biomarker for asthma, in patients with mild asthma.

PRS-060’s Mechanism of Action

Pipeline

Respiratory

Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate PRS-060/AZD1402
Targets

IL4-Rα

Partner

AstraZenica

Commercial Rights

Worldwide
Profit-Share Option

Discovery complete
Preclinical complete
Phase 1 complete
Phase 2 in progress

PRS-060 at a Glance

Function/MOA

Inhibits IL4-Rα (disrupts IL-4 and IL-13 signaling).

Indications

Moderate-to-severe asthma.

Development

Phase 2a trial ongoing

Commercial Rights

Co-development and U.S. co-commercialization rights, including gross margin share.